Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2008-04-03 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Cystic Fibrosis Trial in Children Returns Positive Data 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release from Pharmaxis Ltd dated April 4, 2008, announcing positive data from a Phase II clinical trial for a cystic fibrosis treatment. It contains detailed information about the trial design, results, and context but does not include financial statements or regulatory filings. It is a public announcement of clinical trial results rather than a financial report, regulatory filing, or management discussion. The content is consistent with a Capital/Financing Update or general company update, but since it focuses on clinical trial results and product development news rather than fundraising or capital structure changes, it does not fit CAP. It is not an earnings release or annual/interim report. The document is a press/media release announcing clinical trial results, which is best categorized under Regulatory Filings (RNS) as a general regulatory announcement and company update that does not fit other specific categories.
2008-04-03 English
Change in substantial holding 5 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001, which is a Notice of change of interests of a substantial holder. It details changes in voting power, relevant interests, and associations of substantial shareholders in Pharmaxis Ltd. The form includes tables of shareholdings, dates of changes, and signatures. This type of filing is a regulatory notification about share ownership changes by substantial holders, not a financial report, earnings release, or management discussion. It fits the definition of a Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notice, not just an announcement or certification.
2008-04-02 English
Becoming a substantial holder 5 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 - Notice of Initial Substantial Holder filed under the Corporations Act 2001. It details the substantial shareholding of ABN AMRO Asset Management (Australia) Limited in Pharmaxis Ltd, including voting power, relevant interests, registered holders, consideration paid, and associates. This type of filing is a notification of a major shareholding change, specifically the initial substantial holder notice. It is not an annual report, earnings release, or any other financial report but a regulatory notification about share ownership levels crossing a threshold. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notice, not just an announcement or certification.
2008-04-01 English
Ceasing to be a substantial holder 2 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 under the Corporations Act 2001, specifically a Notice of ceasing to be a substantial holder. It details changes in relevant interests and voting securities of a substantial holder in the company Pharmaxis Ltd. This type of filing is a notification about changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is not a financial report, management information, or any other type of report but a regulatory notice about shareholding changes.
2008-04-01 English
IOC Endorses Aridol 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 28 March 2008 from Pharmaxis Ltd announcing the endorsement of their product Aridol by the International Olympic Committee. It contains promotional and informational content about the product, its approval, and its use in asthma diagnosis for elite athletes. There are no financial statements, regulatory filings, or detailed financial performance data. The document is a press release or announcement rather than a formal financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. Given the nature of the content as a media release announcing a product endorsement, the closest fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2008-03-27 English
Investor Presentation 25 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed investor presentation from March 2008 by Pharmaxis, focusing on the development pipeline, clinical trials, regulatory status, and market strategy for respiratory and autoimmune disease products such as Bronchitol and Aridol. It includes forward-looking statements, clinical trial phases, regulatory approvals, and near-term milestones. The content is typical of an investor presentation aimed at providing financial, strategic, and product development information to investors. There is no indication that this is an official annual report, earnings release, or regulatory filing. The length (15,000 characters) and detailed content support classification as an Investor Presentation rather than a brief announcement or report publication notice.
2008-03-16 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.